Ovid Therapeutics (OVID) TD Cowen 46th Annual Health Care Conference summary

Strategic focus and pipeline overview

• Focused on central nervous system disorders, targeting neural excitation and inhibition balance with small molecule medicines.

• Pipeline built around differentiated mechanisms, aiming for step-change therapeutic and commercial potential.

• Next 6–18 months expected to bring significant data readouts and progress across all assets.

OV329 epilepsy program

• OV329 inhibits GABA aminotransferase, increasing GABA levels and enhancing brain inhibition.

• Recent biomarker data showed brain inhibition at therapeutic levels, with better tolerability than current seizure drugs.

• No anticipated drug-drug interactions or titration challenges; targeting both focal onset and pediatric epilepsies.

• Phase II placebo-controlled study with a 7mg dose to begin soon; safety and tolerability data expected imminently.

• Open-label proof-of-concept study in seizure patients to read out by year-end; expansion into developmental epileptic encephalopathies considered.

OV329 differentiation and safety

• Only company pursuing GABA aminotransferase inhibition for seizures; mechanism differs from sodium/potassium channel drugs.

• OV329 avoids the retinal toxicity seen with first-generation drug Sabril due to different tissue partitioning and rapid clearance.

• Safety and tolerability profile supported by animal and human studies; mild, transient side effects observed.

• Targeting competitive seizure reduction (mid-30% to 50% from baseline) with strong tolerability.